In this special edition episode, hosts break down what the announcement of the 10 drugs selected for Medicare price negotiations under the Inflation Reduction Act means for providers and people with diabetes. The 4 diabetes agents included on the list, which were empagliflozin, dapagliflozin, sitagliptin, and Novo Nordisk-branded insulin products, accounted for more than $16 billion in Part D spending in 2022.